Later calendar year of TDF initiation and baseline ALT >80 U/L were also associated with increased likelihood of HBV DNA suppression. A history of an AIDS-defining condition was associated with HBV suppression and prior 3TC in unadjusted analyses but was not significant in the multivariable model while nadir CD4 remained an independent predictor; prior AIDS-defining condition was therefore not included in the final model. We found no significant difference in HBV suppression between patients who were on TDF alone versus combination therapy with TDF and 3TC or FTC. However, our ability to detect this difference may have been limited because only 37 (9%) patients were on TDF alone for their HBV infection at the start of therapy.
Of the 192 patients who achieved HBV suppression, 111 had at least 2 subsequent HBV measures that enabled us to examine viral breakthrough. Seven of these patients had a recurrent detectable HBV DNA on TDF (all but one with HBV DNA level ≥10,000 IU/mL) between 12 and 87 months after TDF initiation. All but 2 had concurrent HIV suppression at the time of breakthrough.
Among the 127 patients with positive HBeAg who had HBeAg retested on therapy, 30 (24%) had subsequent HBeAg loss, with no difference between groups defined by prior 3TC or HBV suppression. A greater proportion of patients who suppressed their HBV DNA had serum ALT <40 U/L at the end of follow-up than those who did not (68% vs 51%, P = 0.001). Those who suppressed were also less likely to have subsequent FIB-4 scores >3.25 (7% vs 20%, P < 0.001).
Patients included in the analysis had a median of 2 (IQR: 1–3) serum HBV DNA measurements over a median of 15 months (IQR, 7–30) while under observation. Although there was no difference in number of HBV measurements per patient across 3TC exposure groups, the 3TC-naive group was assessed slightly more frequently. Median time from start of TDF to first HBV measurement was 4 months for 3TC-naive and 6.4 months for 3TC-exposed patients (P = 0.02). Median time between HBV follow-up measurements was 4.8 months for 3TC-naive and 7 months for 3TC-exposed patients (P < 0.01). To address whether or not this differential frequency could account for the observed difference in median time until HBV suppression, we examined the proportion of 3TC-exposed and 3TC-naive patients who had HBV measurements before and after the median time to suppression among 3TC-naive patients (17 months). We found that 27% of 3TC-exposed and 32% of 3TC-naive patients had an HBV measurement within 8–16 months (P = 0.25) after TDF initiation, 21% of 3TC-exposed and 22% of 3TC-naive patients (P = 0.81) had an HBV measurement between 16 and 24 months. Thus, the 3TC-exposed and 3TC-naive groups were equally likely to be observed in the early follow-up period that included the median time to suppression among 3TC-naive patients.
To address the possibility that adherence to medications could have accounted for the difference in time to HBV suppression, we conducted survival analysis on the subset of 250 patients who achieved HIV RNA suppression to <50 copies per milliliter by 6 months as a proxy for adherence. Our results were robust in this subset of patients with an aHR of 0.62 for HBV suppression with prior 3TC exposure (95% CI: 0.40 to 0.95, P = 0.03). Notably, the proportion of patients who achieved HIV RNA <50 copies per milliliter by 6 months was comparable between groups defined by prior 3TC (50% among 3TC-naive vs 48% among 3TC exposed, P = 0.80).
We studied the long-term effectiveness of TDF combined with 3TC or FTC in the treatment of HBV in a large cohort of coinfected patients with HBV-HIV in routine clinical care. Ours is the largest observational study to date of coinfected patients with HBV-HIV on TDF. Among the 397 patients in our cohort who had HBV DNA assessed on TDF therapy, most of whom were HBeAg positive, 48% achieved HBV suppression on TDF during a median of 2 years—comparable with rates of suppression reported in longitudinal studies of coinfected patients7,17–19 and treatment-experienced HBV-monoinfected patients20 but lower than other prospective reports of coinfected patients,21 possibly due to the higher prevalence of positive HBeAg and/or lower nadir CD4 in our cohort. HBV suppression was durable among the subset of patients who continued to have HBV DNA measured and HBV viral breakthrough was infrequent, consistent with other long-term studies of coinfected patients.17,22 Failure to achieve HBV DNA <200 IU/mL on TDF was independently associated with a higher baseline HBV DNA level—a well-established finding in both HBV-monoinfected and -coinfected patients.23,24 Notably, we found that lower nadir CD4 count and a history of prior 3TC exposure are independent risk factors for lack of HBV suppression on TDF.
Almost half of our cohort had prior 3TC exposure with a median duration of past therapy of over 3 years. Prolonged 3TC monotherapy for HBV can result in the accumulation of HBV mutations conferring resistance to 3TC in >90% coinfected patients after 4 years of therapy.11,25 Although TDF has been shown to perform well in 3TC-resistant monoinfected26,27 and coinfected7 patients with HBV, we found that prior 3TC therapy was significantly associated with decreased likelihood of HBV DNA suppression with TDF, even after adjusting for potential confounding factors including CD4 count and baseline HBV viral level. Although 3TC and TDF do not seem to share the same pathway for drug resistance, cumulative mutations against 3TC may partially compromise TDF activity as noted in in vitro studies.12,13 Inadequate inhibition of HBV viral replication during treatment with 3TC can also generate compensatory mutations and favor the selection of viral quasispecies with better fitness.28,29 This genetic heterogeneity has been linked with delayed response to TDF in coinfected patients.13
Previous studies have reported a blunted HBV virological response to TDF among 3TC-experienced compared with 3TC-naive, in both coinfected patients with HIV-HBV21,30 and HBV-monoinfected patients.20 In a Spanish cohort of coinfected patients with HIV-HBV, the mean time to HBV suppression was approximately twice as long in 3TC-experienced compared to 3TC-naive patients.30 Other studies not reporting a difference were smaller and had higher proportions of 3TC-experienced patients,7,9,31 which may have limited their ability to detect such differences due to lack of heterogeneity.
We found nadir CD4 count to be an independent predictor of HBV suppression on TDF—with greater likelihood of HBV suppression the higher the nadir CD4 count. Prior reports have noted an association of lower nadir CD4 counts with HBV viremia on 3TC11 and a trend toward delayed response to TDF.18 Baseline CD4 count has also been shown to influence HBV DNA decline among coinfected patients with HIV-HBV on TDF22 and adefovir.32 Patients with greater CD4 count gains on ART seem to be more likely to suppress HBV DNA on antiviral therapy.33 Immune status and restoration have also been shown to predict the kinetics of HBeAg clearance34 and probability of hepatitis B surface antigen (HBsAg) clearance on antiviral therapy,35 both important serological benchmarks of HBV treatment success. These results, including our own, emphasize the key role of the host immune response in antiviral efficacy and clearance of HBV-infected hepatocytes.36 Our findings also complement longitudinal studies that demonstrate greater liver-related mortality among coinfected patients with HIV-HBV with lower nadir CD4 in the ART era4,37 and suggest that uncontrolled HBV viremia in patients with more advanced HIV-mediated immunosuppression may contribute to accelerated liver disease progression.
This study has several limitations. As with any observational study, our findings may have been influenced by unmeasured factors. Information about 3TC resistance in those who were 3TC exposed was not available, and we were not able to assess the relationship between HBV suppression on TDF and outcomes of liver disease severity or cause-specific mortality. Data on outcomes of HBeAg or HBsAg seroconversion were also limited, and antibody to hepatitis delta data not available. Although we could not examine adherence to medications directly, the significant difference in HBV DNA suppression observed between groups defined by prior 3TC was robust in the subset of patients who achieved HIV suppression in 6 months, suggesting that differential adherence did not account for our findings. HBV DNA was also measured infrequently and inconsistently in this cohort, reflecting clinical practice patterns.38 However, patients with baseline and follow-up HBV measurements had similar baseline characteristics to those with missing values. The median time from the start of TDF to first HBV measurement and median time between subsequent follow-up measurements differed by only a few months between 3TC-naive and 3TC-exposed patients. In addition, the majority of patients were assessed by 17 months, which was the median time to suppression among 3TC-naive patients. Our finding that the 3TC-exposed and 3TC-naive groups were equally likely to be observed in the early follow-up period between 8 and 24 months suggests that the observed difference in median time until HBV suppression was not due to differential frequency in HBV measurements. In addition, results of logistical analysis that evaluated HBV DNA suppression by specific time points were similar, suggesting that the timing of HBV testing did not influence our results.
In conclusion, we found that both low nadir CD4 count and prior 3TC treatment were significantly associated with decreased likelihood of HBV DNA suppression among patients treated with TDF after controlling for other factors. These results highlight the role of the host immune response and prior antiviral exposure in long-term HBV treatment effectiveness and provide further support for initiation of ART at higher CD4 counts well before significant immune compromise has occurred. Future research is needed regarding interventions to increase the rate of HBV suppression in coinfected patients with HBV-HIV and the potential link between lack of HBV DNA suppression on therapy and clinical HBV events.
1. Alter MJ. Epidemiology of viral hepatitis and HIV
co-infection. J Hepatol. 2006;44(1 suppl):S6–S9.
2. Benhamou Y. Hepatitis B in the HIV
-coinfected patient. J Acquir Immune Defic Syndr. 2007;45(suppl 2):S57–S65.
3. Puoti M, Torti C, Bruno R, et al.. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44(1 suppl):S65–S70.
4. Thio CL, Seaberg EC, Skolasky R Jr, et al.. HIV
-1, hepatitis B virus
, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–1926.
5. Chen CJ, Yang HI, Su J, et al.. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus
DNA level. JAMA. 2006;295:65–73.
6. Iloeje UH, Yang HI, Jen CL, et al.. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921–931.
7. Benhamou Y, Fleury H, Trimoulet P, et al.. Anti-hepatitis B virus
efficacy of tenofovir
disoproxil fumarate in HIV
-infected patients. Hepatology. 2006;43:548–555.
8. Dore GJ, Cooper DA, Pozniak AL, et al.. Efficacy of tenofovir
disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV
-1 and hepatitis B virus
. J Infect Dis. 2004;189:1185–1192.
9. Lacombe K, Gozlan J, Boelle PY, et al.. Long-term hepatitis B virus
dynamics in HIV
-hepatitis B virus
-co-infected patients treated with tenofovir
disoproxil fumarate. AIDS. 2005;19:907–915.
10. Ristig MB, Crippin J, Aberg JA, et al.. Tenofovir
disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus
-coinfected individuals for whom interferon-alpha and lamivudine
therapy have failed. J Infect Dis. 2002;186:1844–1847.
11. Matthews GV, Bartholomeusz A, Locarnini S, et al.. Characteristics of drug resistant HBV in an international collaborative study of HIV
-HBV-infected individuals on extended lamivudine
therapy. AIDS. 2006;20:863–870.
12. Sheldon J, Camino N, Rodes B, et al.. Selection of hepatitis B virus
polymerase mutations in HIV
-coinfected patients treated with tenofovir
. Antivir Ther. 2005;10:727–734.
13. Lada O, Gervais A, Branger M, et al.. Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV
-HBV-coinfected patients with delayed response to tenofovir
. Antivir Ther. 2012;17:61–70.
14. Kitahata MM, Rodriguez B, Haubrich R, et al.. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol. 2008;37:948–955.
15. Sterling RK, Lissen E, Clumeck N, et al.. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV
/HCV coinfection. Hepatology. 2006;43:1317–1325.
16. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al.. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology. 2011;53:1854–1863.
17. de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al.. Long-term therapy with tenofovir
is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus
. Gastroenterology. 2010;139:1934–1941.
18. Childs K, Joshi D, Byrne R, et al.. Tenofovir
-based combination therapy for HIV
/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV
viraemia. AIDS. 2013;27:1443–1448.
19. Plaza Z, Aguilera A, Mena A, et al.. Influence of HIV
infection on response to tenofovir
in patients with chronic hepatitis B. AIDS. 2013;27:2219–2224.
20. Patterson SJ, George J, Strasser SI, et al.. Tenofovir
disoproxil fumarate rescue therapy following failure of both lamivudine
and adefovir dipivoxil in chronic hepatitis B. Gut. 2011;60:247–254.
21. Alvarez-Uria G, Ratcliffe L, Vilar J. Long-term outcome of tenofovir
disoproxil fumarate use against hepatitis B in an HIV
-coinfected cohort. HIV
22. Matthews GV, Seaberg EC, Avihingsanon A, et al.. Patterns and causes of suboptimal response to tenofovir
-based therapy in individuals coinfected with HIV
and hepatitis B virus
. Clin Infect Dis. 2013;56:e87–e94.
23. Marcellin P, Heathcote EJ, Buti M, et al.. Tenofovir
disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.
24. Peters MG, Andersen J, Lynch P, et al.. Randomized controlled study of tenofovir
and adefovir in chronic hepatitis B virus
infection: ACTG A5127. Hepatology. 2006;44:1110–1116.
25. Benhamou Y, Bochet M, Thibault V, et al.. Long-term incidence of hepatitis B virus
resistance to lamivudine
in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302–1306.
26. van Bommel F, de Man RA, Wedemeyer H, et al.. Long-term efficacy of tenofovir
monotherapy for hepatitis B virus
-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51:73–80.
27. Baran B, Soyer OM, Ormeci AC, et al.. Efficacy of tenofovir
in patients with Lamivudine
failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013;57:1790–1796.
28. Moriconi F, Colombatto P, Coco B, et al.. Emergence of hepatitis B virus
quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine
treatment. J Antimicrob Chemother. 2007;60:341–349.
29. Thio CL. Virology and clinical sequelae of drug-resistant HBV in HIV
-HBV-coinfected patients on highly active antiretroviral therapy. Antivir Ther. 2010;15(3 pt B):487–491.
30. Tuma P, Bottecchia M, Sheldon J, et al.. Prior lamivudine
(LAM) failure may delay time to complete HBV-DNA suppression in HIV
patients treated with tenofovir
plus LAM. Hepatology. 2008;48(4 suppl):740A–741A.
31. Audsley J, Arrifin N, Yuen LK, et al.. Prolonged use of tenofovir
/hepatitis B virus
(HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine
HBV polymerase mutations. HIV
32. Cortez KJ, Proschan MA, Barrett L, et al.. Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine
-resistant HBV-infected patients with or without HIV
Clin Trials. 2013;14:149–159.
33. Nunez M, Ramos B, Diaz-Pollan B, et al.. Virological outcome of chronic hepatitis B virus
infection in HIV
-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses. 2006;22:842–848.
34. Maylin S, Boyd A, Lavocat F, et al.. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir
in antiretroviral-experienced HIV
-hepatitis B virus
-infected patients. AIDS. 2012;26:939–949.
35. Arendt E, Jaroszewicz J, Rockstroh J, et al.. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV
co-infected patients. Viral Immunol. 2012;25:442–447.
36. Rehermann B. Immune responses in hepatitis B virus
infection. Semin Liver Dis. 2003;23:21–38.
37. Bonacini M, Louie S, Bzowej N, et al.. Survival in patients with HIV
infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18:2039–2045.
38. Jain MK, Opio CK, Osuagwu CC, et al.. Do HIV
care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Clin Infect Dis. 2007;44:996–1000.